Ovarian function during use of Nestorone® subdermal implants1


      Nestorone® progestin (NES) is a potent 19-nor-progesterone derivative which is biologically inactive when administered orally; however, it is an excellent option for implant contraception. The objective of this study was to evaluate ovarian function during use of either one 4-cm or two 3-cm NES implants for 24 months. A total of 60 volunteers were enrolled in each dose group. Vaginal ultrasound (VUS) and blood sampling for determinations of estradiol (E2), progesterone (P) and NES serum levels were carried out twice a week for 6 consecutive weeks, beginning in months 1, 6, 12, 18, and 24 of implant use. Serum levels of NES declined with time, with a more pronounced decrease during the first 18 months of implant use; thereafter, NES levels remained stable until the end of the study at 24 months. Luteal activity was very infrequent during the first year of use (<3%) but increased during the second year, occurring in 27% and 35% of the sampling periods in the 1-implant group, and 2% and 16% of the sampling periods in the 2-implant group, at months 18 and 24 of use, respectively. No luteal activity was observed with NES levels above 80 pmol/L. Serum P levels in periods of luteal activity were significantly lower than those of controls. Persistent anovulatory follicles were the most common VUS finding and this was associated with E2 levels that remained within the normal range (101–1500 pmol/L) in the majority of the sampling periods studied. Considering that a single implant offers advantage for insertion and removal, a new single NES implant is being developed with a slightly higher release rate, to reduce effectively the incidence of ovulation and provide a greater margin of safety beyond 2 years.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fraser I.S
        • Tiitinen A
        • Affandi B
        • et al.
        Norplant® consensus statement and background review.
        Contraception. 1998; 57: 1-9
        • Alvarez-Sanchez F
        • Brache V
        • Faundes A
        Recent experience with and future directions of contraceptive implants and injectable contraceptives.
        Curr Opin Obstet Gynecol. 1993; 5: 805-814
        • Ladipo O
        • Coutinho E.M
        Contraceptive implants.
        Curr Opin Obstet Gynecol. 1994; 6: 564-569
        • Coutinho E.M
        • Da Silva A.R
        • Kraft H.G
        Fertility control with subdermal Silastic capsules containing a new progestin (ST-1435).
        Int J Fertil. 1976; 21: 103-108
        • Lähteenmäki P
        • Weiner E
        • Lähteenmäki P
        • Johansson E.D
        • Luukkainen T
        Pituitary and ovarian function during contraception with one subcutaneous implant releasing a progestin, ST 1435.
        Contraception. 1982; 25: 299-306
        • Kurunmaki H
        • Toivonen J.P
        • Luukkainen T
        Contraception with subdermal ST-1435 capsules.
        Contraception. 1985; 31: 305-318
        • Lähteenmäki P.L.A
        • Lähteenmäki P
        Concentration-dependent mechanisms of ovulation inhibition by the progestin ST-1435.
        Fertil Steril. 1985; 44: 20-24
        • Laurikka-Routti M
        • Haukkamaa M
        A contraceptive subdermal implant releasing the progestin ST-1435.
        Fertil Steril. 1992; 58: 1142-1147
        • Haukkamaa M
        • Laurikka-Routti M
        • Heikinheimo O
        • Moo-Young A
        Contraception with subdermal implants releasing the progestin ST-1435.
        Contraception. 1992; 45: 49-55
        • Diaz S
        • Schiappacasse V
        • Pavez M
        • et al.
        Clinical trial with Nestorone subdermal contraceptive implants.
        Contraception. 1995; 51: 33-38
      1. WHO Special Programme of Research, Development and Research Training in Human Reproduction. Programme for the Provision of Matched Assay Reagents for the RIA of Hormones in Reproductive Physiology, 16th ed, Method Manual. Sufi SB. Donaldson A, Jeffcoate SL, WHO Collaborating Centre for Immunoassay, London, UK, 1992.

        • Lähteenmäki P
        • Weiner E
        • Lähteenmäki P.L.A
        • Johansson E
        • Luukkainen T
        Contraception with subcutaneous capsules containing ST-1435. Pituitary and ovarian function and plasma levels of ST-1435.
        Contraception. 1981; 23: 63-75
        • Nars P.W
        • Hunter W.M
        A method for labeling oestradiol-17β with radioiodine for radioimmunoassay.
        J Endocrinol. 1973; 37: 47
        • Makarainen L
        • Van Beek A
        • Tuomivaara L
        • Asplund B
        • Bennink H.C
        Ovarian function during the use of a single contraceptive implant.
        Fertil Steril. 1998; 69: 714-721
        • Barbosa I
        • Coutinho E
        • Hirsch C
        • Ladipo O
        • Olsson S.E
        • Ulmsten U
        Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
        Fertil Steril. 1996; 65: 724-729
        • Devoto L
        • Kohen P
        • Barnhart K
        • et al.
        Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant).
        Hum Reprod. 1997; 12: 708-713
        • Croxatto H.B
        • Diaz S
        • Pavez M
        • Mirda P
        • Brandeis A
        Plasma progesterone levels during long-term treatment with levonorgestrel Silastic implants.
        Acta Endocrinol (Copenh). 1982; 101: 307-311
        • Brache V
        • Alvarez F
        • Faúndes A
        • Tejada A.S
        • Cochón L
        Ovarian endocrine function through five years continuous treatment with Norplant® subdermal implants.
        Contraception. 1990; 41: 160-177
        • Sivin I
        • Viegas O
        • Campodonico I
        • et al.
        Clinical performance of a new two-rod levonorgestrel contraceptive implant.
        Contraception. 1997; 55: 73-80
        • Sivin I
        • Mishell Jr, D.R
        • Darney P
        • Wan L
        • Christ M
        Levonorgestrel capsule implants in the United States.
        Obstet Gynecol. 1998; 92: 337-344
        • Croxatto H.B
        • Diaz S
        • Pavez M
        • Brandeis A
        Estradiol plasma levels during long-term treatment with Norplant® subdermal implants.
        Contraception. 1988; 38: 465-474
        • Jackson R
        • Newton J.R
        Pharmacodynamics of a contraceptive vaginal ring releasing 3-keto-desogestrel.
        Contraception. 1989; 39: 653-664
        • Shoupe D
        • Horenstein J
        • Mishell Jr, D.R
        • Lacarra M
        • Medearis A
        Characteristics of ovarian follicular development in Norplant® implants users.
        Fertil Steril. 1991; 55: 766-770
        • Shaaban M.M
        • Segal S
        • Salem H.T
        • Ghaneimah S
        • Khalifa E.A.M
        • Ahmed A.G
        Sonographic assessment of ovarian and endometrial changes during long-term Norplant® use and their correlation with hormonal levels.
        Fertil Steril. 1993; 59: 998-1002
        • Alvarez F
        • Brache V
        • Faundes A
        • Tejada A.S
        • Thevenin F
        Ultrasonographic and endocrine evaluation of ovarian function among Norplant® implants users with regular menses.
        Contraception. 1996; 54: 275-279
        • Chitlange S.M
        • Shah R.S
        • Hazari K.T
        • Anadkumar T.C
        • Puri C.P
        Ultrasonographic monitoring of ovarian follicles in women using norethisterone for contraception.
        Int J Gynecol Obstet. 1996; 53: 31-34
        • Weiner E
        • Johansson E.D.B
        • Wide L
        Inhibition of the positive feedback of estradiol during treatment with subcutaneous implants of d-norgestrel.
        Contraception. 1976; 13: 287-297
        • Faundes A
        • Brache V
        • Alvarez F
        Functional life-span of the dominant follicle in pharmacologically induced anovulatory cycles.
        Hum Reprod. 1996; 11: 114-116
        • Croxatto H.B
        • Mäkäräinen L
        The pharmacodynamics and efficacy of Implanon®. An overview of the data.
        Contraception. 1998; 58: 91S-97S
        • Lähteenmäki P.L.A
        • Diaz S
        • Miranda P
        • Croxatto H
        • Lähteenmäki P
        Milk and plasma concentrations of the progestin ST-1435 in women treated parenterally with ST-1435.
        Contraception. 1990; 42: 555-562
        • Diaz S
        • Croxatto H.B
        Contraception in lactating women.
        Curr Opin Obstet Gynecol. 1993; 5: 815-822
        • Odlind V
        • Lithell H
        • Selinus I
        • Vessby B
        Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST-1435.
        Contraception. 1985; 31: 123-130
        • Laurikka-Routti M
        Serum lipids, blood pressure, body weight, and serum chemistry in women using subcutaneous contraceptive implants releasing the progestin ST-1435.
        Obstet Gynecol. 1992; 80: 855-859
      2. Why family planning matters. Population Reports1999, 25, Series J, No 49.